Abstract 800: ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia

MLA

Xiaoli Huang, et al. “Abstract 800: ABBV-744, a First-in-Class and Highly Selective Inhibitor of the Second Bromodomain of BET Family Proteins, Displays Robust Activities in Preclinical Models of Acute Myelogenous Leukemia.” Cancer Research, vol. 78, July 2018, p. 800. EBSCOhost, https://doi.org/10.1158/1538-7445.am2018-800.

APA

Xiaoli Huang, Terrance J. Magoc, Debra Ferguson, Emily J. Faivre, Xiaoyu Lin, Paul Hessler, Richard J. Bellin, Warren M. Kati, Daniel H. Albert, Lloyd T. Lam, Mai Ha Bui, Tamar Uziel, Denise Wilcox, Keith F. McDaniel, & Yu Shen. (2018). Abstract 800: ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia. Cancer Research, 78, 800. https://doi.org/10.1158/1538-7445.am2018-800

Chicago

Xiaoli Huang, Terrance J. Magoc, Debra Ferguson, Emily J. Faivre, Xiaoyu Lin, Paul Hessler, Richard J. Bellin, et al. 2018. “Abstract 800: ABBV-744, a First-in-Class and Highly Selective Inhibitor of the Second Bromodomain of BET Family Proteins, Displays Robust Activities in Preclinical Models of Acute Myelogenous Leukemia.” Cancer Research 78 (July): 800. doi:10.1158/1538-7445.am2018-800.